Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Neoplasms 3Recurrence 2Wilms Tumor 1Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Death 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Genes, p53 × Clear all
NCT04758455 2021-02-17

The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence

Mansoura University

Phase NA Unknown
75 enrolled
Genitourinary

Death, Wilms Tumor, Recurrence

NCT02435186 2015-05-06

p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Shenzhen SiBiono GeneTech Co.,Ltd

Phase 2 Unknown
100 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡